MEI Pharma, Inc. Common Stock, also called MEI Pharma, is a pharmaceutical company, which engages in the clinical development of therapies for cancer. Read More Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA. The listed name for MEIP is MEI Pharma, Inc. Common Stock.